2023
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. Journal Of Clinical Oncology 2023, 41: 1036-1036. DOI: 10.1200/jco.2023.41.16_suppl.1036.Peer-Reviewed Original ResearchMetastatic breast cancerLobular histologyBreast cancerHER2 IHCGenomic alterationsComprehensive genomic profiling studyPD-L1 gene amplificationImmune checkpoint inhibitor treatmentMicrosatellite instabilityAxillary LN metastasisMetastatic site biopsySubset of ptsStage IV diseaseCheckpoint inhibitor treatmentPD-L1 expressionTumor mutational burdenMutations/MbMSI-high statusHER2 IHC resultsGenomic profiling studiesSite biopsiesSP142 assayLN metastasisMetastatic diseaseHigh TMBHRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Oxnard G, Huang R, Pusztai L. HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2023, 41: 539-539. DOI: 10.1200/jco.2023.41.16_suppl.539.Peer-Reviewed Original ResearchEarly-stage breast cancerPrimary breast cancerEarly breast cancerBreast cancerStage IHR-/HER2HRR deficiencyPALB2 mutationsEarly-stage primary breast cancerPARP inhibitorsStage IV diseaseHormone receptor statusMonths of diagnosisPositive breast cancerHomologous recombination repairComprehensive genomic profilingHRD signaturesClinical trial dataHigh rateSEER studySomatic BRCAAdjuvant therapyAdvanced diseaseReceptor statusBC subtypes
2018
Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy
Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez‐MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK. Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy. The Oncologist 2018, 24: 313-318. PMID: 30139836, PMCID: PMC6519755, DOI: 10.1634/theoncologist.2018-0213.Peer-Reviewed Original ResearchConceptsDe novo stage IVProgression-free survivalMetastatic breast cancerHigher progression-free survivalPositive metastatic breast cancerExcellent long-term outcomesOverall survivalLong-term outcomesNED statusBreast cancerStage IVOS ratesLocoregional therapyRandomized studyDe novo stage IV diseaseDisease statusHER2-Targeted TherapyMedian overall survivalStage IV diseaseFirst-line therapyTrastuzumab-based therapyEstrogen receptor-positive statusPositive breast cancerImportant therapeutic goalNED patients
2017
Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.
Wong Y, Raghavendra A, Hatzis C, Irizarry J, Vega T, Barcenas C, Chavez-Mac Gregor M, Valero V, Tripathy D, Pusztai L, Murthy R. Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy. Journal Of Clinical Oncology 2017, 35: 1021-1021. DOI: 10.1200/jco.2017.35.15_suppl.1021.Peer-Reviewed Original ResearchProgression-free survivalLonger progression-free survivalPositive breast cancerHER2-positive cancersMedian OSNED patientsOS ratesFree survivalOverall survivalPositive cancersBreast cancerDe novo stage IV diseaseHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2MD Anderson Cancer CenterStage IV diseaseAggressive multimodality therapyEvidence of diseaseFirst-line therapyGrowth factor receptor 2Year of diagnosisEarly-stage patientsAnderson Cancer CenterLong-term survival
2009
Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer
Andreopoulou E, Hatzis C, Booser D, Valero V, Wallace M, Sotiriou C, Hortobagyi G, Pusztai L, Symmans W. Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer. Journal Of Clinical Oncology 2009, 27: 1044-1044. DOI: 10.1200/jco.2009.27.15_suppl.1044.Peer-Reviewed Original ResearchER-positive breast cancerBreast cancerEstrogen receptorPathologic stageAJCC stageProgesterone receptorStage IIIAdvanced ER-positive breast cancerExpression levelsStage IV diseaseER gene expressionClinical samplesPatient clinical samplesPgR expression levelsInitial presentationTumor dependenceExpression of GAPDHAdvanced stageCancerGene expressionGenomic pathwayGAPDH gene expressionReceptor geneGene expression profilesFurther studies